Literature DB >> 11194706

Oxidative markers in diabetic ketoacidosis.

M C Vantyghem1, M Balduyck, F Zerimech, A Martin, C Douillard, S Bans, P M Degand, J Lefebvre.   

Abstract

UNLABELLED: Oxidative stress has been implicated in the pathogenesis of the chronic complications of diabetes mellitus but little is known in diabetic ketoacidosis (DKA). The aim of this work was to determine whether lipid peroxidation, as assessed by measuring malondialdehyde (MDA, a prooxidant) and antioxidant status (TAS, an index of antioxidant defenses), is modified in DKA, and also whether any observed abnormalities were related to metabolic disturbances.
METHODS: four groups of patients were studied, comprising 19 patients with DKA, massive ketonuria and plasma standard bicarbonate levels below 16 mmol/l (group 1); 20 patients with poorly controlled diabetes, glycated hemoglobin (HbA1c) above 8% and plasma bicarbonate levels above 16 mmol/l (group 2); 11 patients with well-controlled diabetes and HbA1c below 8% (group 3); and 10 non-diabetic, non-obese control subjects (group 4). Metabolic parameters, MDA levels and TAS were assessed in the plasma of the four groups of subjects.
RESULTS: mean plasma MDA and TAS values were significantly different among the four groups (respectively p < 0.001 and p < 0.01). Mean plasma MDA value was significantly higher in group 1 than in group 3 (p < 0.02) and group 4 (p < 0.001) but was not different from that in group 2. Mean plasma MDA value in group 2 was significantly lower than that in group 4 (p = 0.002). Mean plasma TAS value in group 1 was significantly lower than in groups 3 (p < 0.002) and 4 (p < 0.05). Mean plasma TAS value was significantly lower in group 2 than in group 4 (p<0.05). Plasma MDA values in the diabetic patients (groups 1+2+3) were not related to any clinical characteristics (BMI, age, duration of the disease) or metabolic parameters (glycemia, HbA1c bicarbonates, blood urea nitrogen, phosphatemia, lipids), while plasma TAS values correlated negatively with glycemia, osmolality and HbA1c. A significant relationship was also found between TAS and HbA1c in group 1 (p < 0.05) and between MDA and HbA1c in group 3 (p < 0.05). Correlations were also found between TAS and phosphatemia in group 1 (p < 0.01) and between MDA and phosphatemia in group 2 (p < 0.01). A positive relationship between MDA and cholesterol levels was found in group 1 (p < 0.01). In conclusion, MDA values are increased and TAS values decreased in DKA and poorly controlled diabetes, and tend to correlate more with markers of diabetic imbalance than with markers of acute metabolic disturbances of DKA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11194706     DOI: 10.1007/BF03345062

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

Review 1.  The metabolic derangements and treatment of diabetic ketoacidosis.

Authors:  D W Foster; J D McGarry
Journal:  N Engl J Med       Date:  1983-07-21       Impact factor: 91.245

2.  Total radical-trapping antioxidant parameter in NIDDM patients.

Authors:  A Ceriello; N Bortolotti; E Falleti; C Taboga; L Tonutti; A Crescentini; E Motz; S Lizzio; A Russo; E Bartoli
Journal:  Diabetes Care       Date:  1997-02       Impact factor: 19.112

3.  Increased lipoperoxide value and glutathione peroxidase activity in blood plasma of type 2 (non-insulin-dependent) diabetic women.

Authors:  H Kaji; M Kurasaki; K Ito; T Saito; K Saito; T Niioka; Y Kojima; Y Ohsaki; H Ide; M Tsuji
Journal:  Klin Wochenschr       Date:  1985-08-16

4.  Red cell peroxide metabolism in diabetes mellitus.

Authors:  A Bono; G Caimi; A Catania; A Sarno; L Pandolfo
Journal:  Horm Metab Res       Date:  1987-06       Impact factor: 2.936

5.  Lipid peroxidation and trace element status in diabetic ketotic patients: influence of insulin therapy.

Authors:  P Faure; P Corticelli; M J Richard; J Arnaud; C Coudray; S Halimi; A Favier; A M Roussel
Journal:  Clin Chem       Date:  1993-05       Impact factor: 8.327

6.  Cytotoxic effects of cytokines on rat islets: evidence for involvement of free radicals and lipid peroxidation.

Authors:  A Rabinovitch; W L Suarez; P D Thomas; K Strynadka; I Simpson
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

7.  Evolution of metabolic and functional derangements of pancreatic islets in phosphate depletion.

Authors:  E Levi; G Z Fadda; C Ozbasli; S G Massry
Journal:  Endocrinology       Date:  1992-11       Impact factor: 4.736

8.  Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production.

Authors:  A Rabinovitch; W L Suarez-Pinzon; K Strynadka; J R Lakey; R V Rajotte
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

9.  Increase in the glucosylated form of erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity.

Authors:  K Arai; S Iizuka; Y Tada; K Oikawa; N Taniguchi
Journal:  Biochim Biophys Acta       Date:  1987-05-19

10.  Oxygen free radical scavengers protect rat islet cells from damage by cytokines.

Authors:  W Sumoski; H Baquerizo; A Rabinovitch
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

View more
  11 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  Hemolyzed plasma samples in diabetic ketoacidosis (DKA).

Authors:  L Sojo; A M Wägner; J Ordóñez; R Corcoy
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

3.  Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis.

Authors:  William H Hoffman; Sandra L Siedlak; Yang Wang; Rudy J Castellani; Mark A Smith
Journal:  Brain Res       Date:  2010-10-30       Impact factor: 3.252

4.  Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis.

Authors:  Shao-gang Ma; Yue Jin; Wei Xu; Wen Hu; Feng Bai; Xiao-juan Wu
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

5.  Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia.

Authors:  Ajay Chaudhuri; Guillermo E Umpierrez
Journal:  J Diabetes Complications       Date:  2012-05-31       Impact factor: 2.852

6.  Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes.

Authors:  Johannes Pleiner; Friedrich Mittermayer; Herbert Langenberger; Christine Winzer; Georg Schaller; Giovanni Pacini; Alexandra Kautzky-Willer; Andrea Tura; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

7.  Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis.

Authors:  Shao-Gang Ma; Yao Jin; Wen Hu; Feng Bai; Wen Xu; Wei-Nan Yu
Journal:  Biomark Insights       Date:  2012-03-14

8.  Evaluation of Pre-Treatment and Post-Treatment S100B, Oxidant and Antioxidant Capacity in Children with Diabetic Ketoacidosis.

Authors:  Cemil Kaya; Ali Ataş; Nurten Aksoy; Esra Celen Kaya; Mahmut Abuhandan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-06

Review 9.  Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress.

Authors:  Sergio Rosales-Corral; Dun-Xian Tan; Lucien Manchester; Russel J Reiter
Journal:  Oxid Med Cell Longev       Date:  2015-02-26       Impact factor: 6.543

10.  The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-induced diabetic rats.

Authors:  Munire Kuru Karabas; Mediha Ayhan; Engin Guney; Mukadder Serter; Ibrahim Meteoglu
Journal:  ISRN Endocrinol       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.